Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §5

SELECT — citing documents

Every Institute document that draws on this record.

Document identifier
CEI-TR-0010/5
Series
Trial abstract
Version
2.3
Published
07 Jan 2023
Last reviewed
07 Mar 2024
Next review
07 Mar 2026
Identifier
10.71829/cei.trial.10
Certainty
High
Cycle
2023 Q1
Phase
Phase 3
Status
Reported

§5Citing documents

This page records every Institute document that draws on SELECT. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.

§5.1Monograph evidence extracts

Table 7. Monograph evidence extracts that draw on this trial.

§5.2Evidence syntheses

Table 8. Evidence syntheses that include this trial among their contributing studies.

SynthesisReview typeCertainty
Glucagon-like peptide-1 receptor agonists for weight reduction in adults with obesityIntervention reviewHigh
Dual and triple incretin receptor agonists compared with single glucagon-like peptide-1 receptor agonists for…Network meta-analysisModerate
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonistsIntervention reviewHigh
Weight change after discontinuation of an incretin receptor agonistIntervention reviewModerate
Gastrointestinal adverse events with incretin receptor agonistsSafety reviewHigh
Change in lean mass during pharmacologically induced weight reductionScoping reviewLow
Oral compared with injectable presentations of glucagon-like peptide-1 receptor agonismNetwork meta-analysisModerate
The rodent thyroid C-cell signal and its human relevanceSafety reviewLow
Acute pancreatitis with incretin-based therapiesSafety reviewModerate
Cardiovascular benefit in primary compared with secondary preventionIntervention reviewModerate
Distribution of access to obesity pharmacotherapyMethodological reviewLow
Transitivity in the incretin networkMethodological reviewModerate
Semaglutide in obesity and overweight in adults: effect on the anchor outcomeIntervention reviewHigh
Semaglutide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: effect on the anchor…Intervention reviewHigh
Semaglutide in obesity and overweight in adults: tolerability and discontinuationSafety reviewHigh
Semaglutide in atherosclerotic cardiovascular disease and cardiovascular risk reduction: tolerability and…Safety reviewHigh
Semaglutide in obesity and overweight in adults: durability of effectIntervention reviewHigh

§5.3Other records in the same programme

Table 9. Other records in the SELECT — semaglutide cardiovascular outcomes without diabetes.

RecordTypePhaseStatus
SELECT-ADHERENCEProgramme record3Reported

§5.4Reference

The published report or reports the Institute holds for this trial[1,2].

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563 · PMID 37952131
  2. Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barrientos-Pérez M, Colhoun HM, Cercato C, Conway L, Kushner RF, Lincoff AM. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine 2024;30(7):2049–2057. doi:10.1038/s41591-024-02996-7 · PMID 38740993

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.